share_log

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax Pharmaceuticals | CORRESP: CORRESP

Virpax製藥 | CORRESP：信函
美股SEC公告 ·  05/15 00:35
牛牛AI助理已提取核心訊息
Virpax Pharmaceuticals, Inc. has taken a significant step towards its capital raising efforts by filing a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). The filing, identified by File No. 333-278796, was made on May 14, 2024. A.G.P./ALLIANCE GLOBAL PARTNERS, acting as the Sole Placement Agent, has formally requested the SEC to declare the Registration Statement effective by 5:00 p.m. Eastern Time on the same day, or as soon as possible thereafter. This move is in accordance with Rule 461 of the Securities Act of 1933. The company has also indicated that, in line with Rule 460, it expects to distribute copies of the Preliminary Prospectus dated May 13, 2024, to a variety of potential investors to ensure adequate distribution. A.G.P./ALLIANCE GLOBAL PARTNERS has confirmed compliance with its obligations under Rule 15c2-8 of the Securities Exchange Act of 1934, which includes the delivery requirements of the Preliminary Prospectus to prospective investors.
Virpax Pharmaceuticals, Inc. has taken a significant step towards its capital raising efforts by filing a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC). The filing, identified by File No. 333-278796, was made on May 14, 2024. A.G.P./ALLIANCE GLOBAL PARTNERS, acting as the Sole Placement Agent, has formally requested the SEC to declare the Registration Statement effective by 5:00 p.m. Eastern Time on the same day, or as soon as possible thereafter. This move is in accordance with Rule 461 of the Securities Act of 1933. The company has also indicated that, in line with Rule 460, it expects to distribute copies of the Preliminary Prospectus dated May 13, 2024, to a variety of potential investors to ensure adequate distribution. A.G.P./ALLIANCE GLOBAL PARTNERS has confirmed compliance with its obligations under Rule 15c2-8 of the Securities Exchange Act of 1934, which includes the delivery requirements of the Preliminary Prospectus to prospective investors.
Virpax藥品公司已向美國證券交易委員會（SEC）提交S-1表格的註冊申報，爲籌集資金邁出了重要一步。該申報的文件號爲333-278796，提交於2024年5月14日。行動當天，總代理ALLIANCE GLOBAL PARTNERS正式要求SEC於當天下午5:00（美國東部時間）將該註冊申報生效，或儘快在之後生效。此舉符合《證券法》第461條的規定。公司還表示，根據第460條的規定，它預計將分發2024年5月13日的初步招股意向書副本給各種可能的投資者以確保充分分發。ALLIANCE GLOBAL PARTNERS已確認遵守《證券交易法》第15c2-8條的義務，包括向擬定投資者交付初步招股意向書的要求。
Virpax藥品公司已向美國證券交易委員會（SEC）提交S-1表格的註冊申報，爲籌集資金邁出了重要一步。該申報的文件號爲333-278796，提交於2024年5月14日。行動當天，總代理ALLIANCE GLOBAL PARTNERS正式要求SEC於當天下午5:00（美國東部時間）將該註冊申報生效，或儘快在之後生效。此舉符合《證券法》第461條的規定。公司還表示，根據第460條的規定，它預計將分發2024年5月13日的初步招股意向書副本給各種可能的投資者以確保充分分發。ALLIANCE GLOBAL PARTNERS已確認遵守《證券交易法》第15c2-8條的義務，包括向擬定投資者交付初步招股意向書的要求。
有用
沒用

該公告為獨立文件：

獨立文件1

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。